Table 2.
prognostic factors of distant progression free survival and overall survival
| PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR | IC95 | p | p | HR | IC95 | p | p | |
| PET-TDM | 0.59 | 0.44 | [0.20,0.94] | 0.068 | ||||
| Oligometastatic site | 0.136 | 0.02 | 0.37 | |||||
| Indication (oligometastatic spectrum) (ref = oligometastases) | 0.04 | 0.029 | 0.03 | 0.02 | ||||
| Center | 0.498 | 0.477 | ||||||
| Age (ref= > 63 y) | 0.69 | [0.43,1.12] | 0.134 | 0.42 | [0.23,0.76] | 0.004 | 0.003 | |
| Gender (ref = male) | 0.89 | [0.55,1.46] | 0.65 | 1.11 | [0.62,1.98] | 0.731 | ||
| Smoking habits | 0.66 | [0.34,1.26] | 0.226 | 1.25 | [0.53,2.95] | 0.593 | ||
| Comorbidities | 0.999 | [0.61,1.65] | 0.992 | 1.42 | [0.78,2.57] | 0.223 | ||
| Free interval (ref > 516 days) | 2.41 | [1.28,4.51] | 0.001 | 3.23 | [1.37,7.61] | 0.002 | ||
| Primary cancer controlled | 1.24 | [0.63,2.44] | 0.498 | 1.14 | [0.48,2.70] | 0.77 | ||
| Number of metastatic lesions =2 (ref = 1) | 1.18 | [0.53,2.60] | 0.695 | 0.962 | [0.38,2.43] | 0.928 | ||
| Number of previous systemic treatment lines | 0.777 | 0.133 | ||||||
| Synchronous lesion (ref = metachronous) | 0.90 | [0.53,1.54] | 0.716 | 1.09 | [0.60,1.99] | 0.779 | ||
| Histology | 0.985 | 0.685 | ||||||
| EGFR mutation or ALK translocation | 1.56 | [0.77,3.15] | 0.252 | 0.83 | [0.37,1.85] | 0.581 | ||
| Initial T stage (ref = T1) | ||||||||
| T2 | 1.3 | [0.66,2.58] | 0.2 | 1.79 | [0.73,4.4] | 0.02 | 0.008 | |
| T3 | 0.8 | [0.39,1.75] | 0.79 | [0.29,2.2] | ||||
| T4 | 1.9 | [0.84,4.5] | 3 | [1.05,8.4] | ||||
| Initial N+ status (ref = N0) | 1.71 | [1.01,2.90] | 0.035 | 0.022 | 1.29 | [0.69,2.425] | 0.411 | |
Boldface entries = statistically significant